Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B
Phase of Trial: Phase I/II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs Birinapant (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors TetraLogic Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 09 Oct 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 08 May 2015 According to a TetraLogic Pharmaceuticals media release, enrolment has been temporarily halted due to cranial nerve palsies observed in the first cohort.